DRW Securities’s Alzamend Neuro ALZN Stock Holding History

DRW Securities’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-116,319	Closed	-$212K	–	1253
2025 Q4	$212K	Buy	116,319 +25,074	+27%	+$56.9K	0.01%	937
2025 Q3	$217K	Buy	+91,245	New	+$237K	﹤0.01%	1037

Other funds holding ALZN

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

DRW Securities's ALZN Position: Q1 2026 in Review

DRW Securities sold out of Alzamend Neuro (ALZN) in Q1 2026, closing a stake of 116,319 shares — an estimated $212K sold.

DRW Securities first reported a position in ALZN in Q3 2025 and held it in 2 quarters. The position peaked at $217K in Q3 2025. 12 funds tracked by Wall St. Rank hold ALZN as of Q1 2026.

DRW Securities reported no remaining Alzamend Neuro position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 116,319 Alzamend Neuro shares in Q1 2026, an estimated $212K.
DRW Securities first reported a position in Alzamend Neuro in Q3 2025 and held it in 2 quarters.
DRW Securities's Alzamend Neuro position peaked at $217K in Q3 2025.
12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.